CTNI-66. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Primary central nervous system lymphoma (PCNSL) is known as one of the incurable brain tumors. In March 2020, Tirabrutinib (TIR), a second-generation oral Bruton’s tyrosine kinase inhibitor, was approved for the indication of relapsed or refractory PCNSL (rrPCNSL) based on the results of a phase I/I...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Mishima, Kazuhiko, Narita, Yoshitaka, Nagane, Motoo, Terui, Yasuhito, Arakawa, Yoshiki, Yonezawa, Hajime, Asai, Katsunori, Fukuhara, Noriko, Sugiyama, Kazuhiko, Shinojima, Naoki, Aoi, Arata, Nishikawa, Ryo
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Clinical Trials: Non-Immunologic
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650894/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.232
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares